Godwin A. Dziwornu, Donald Seanego, Stephen Fienberg, Venkata S. Sypu, Nicolaas Salomane, Liezl Krugmann, Dale Taylor, Keabetswe Masike, Mathew Njoroge, Nonlawat Boonyalai, Marcus C. S. Lee, Luiz C. Godoy, Charisse Flerida Pasaje, Jacquin C. Niles, Gregory S. Basarab, Lauren B. Coulson, Sandeep R. Ghorpade, Kelly Chibale
J. Med. Chem. 2025, 68, 20, 21878–21891
Previously reported antimalarial Plasmodium phosphatidylinositol 4-kinase IIIβ 2,8-diaryl-1,5-naphthyridine inhibitors have shown suboptimal physicochemical and pharmacokinetic properties. A focused target-based structure–activity relationship and structure–property optimization studies identified several compounds with good target and whole-cell activities and improved physicochemical properties. A new frontrunner compound 27 showed an improved pharmacokinetic profile and reduced parasitaemia (91% at 4 × 50 mg/kg QD doses) in the humanized NOD-scid IL-2Rγnull mouse model of Plasmodium falciparum malaria. Compound 27 poses no hERG channel inhibition at high concentrations or mammalian cytotoxicity but shows low selectivity against related human lipid kinases (PI3Kα and PI4Kβ); however, significantly higher selectivity margins were observed against the human MINK1 and MAP4K4 kinases.